Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells - Wikidata - wikimedia - TriplyDB

Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells

Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells

http://www.wikidata.org/entity/Q34978267

about

Trial watch - inhibiting PARP enzymes for anticancer therapy Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.Estrogen receptor α and aryl hydrocarbon receptor independent growth inhibitory effects of aminoflavone in breast cancer cells.Inhibitors of PARP-1 exert inhibitory effects on the biological characteristics of hepatocellular carcinoma cells in vitro Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.Advances in small-molecule drug discovery for triple-negative breast cancer.PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition.Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo Emerging therapeutic targets in metastatic progression: A focus on breast cancer.Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®.Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib A review of iniparib in ovarian cancer.PARP inhibitors: polypharmacology versus selective inhibition.Appraising iniparib, the PARP inhibitor that never was--what must we learn?Tankyrases: structure, function and therapeutic implications in cancer.Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.Advances in PARP inhibitors for the treatment of breast cancer.INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.Rucaparib: First Global Approval.Molecular pathways: targeting PARP in cancer treatment.Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines.Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets.H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.PARP inhibitors: current status and implications for anticancer therapeutics.Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype.Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors.Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy.Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy.

P2860

Q26745673-63EFD01B-B29A-48A6-9A73-93E035B90101 Q26851765-8E51EA0E-C368-4874-BB3F-7739D3A79F9A Q27304386-7F0E4EA5-E856-42FB-A83F-42123C8C39E5 Q33557916-AB4C7374-0528-4DB7-B352-E3DD5C602EC9 Q33603605-E7C7F2C7-6B01-4475-B03D-D77D96CE48D4 Q33680008-74ADA100-C0E3-4DBD-9062-004D9EC41225 Q33828196-7898B9AE-A791-4E00-A83D-24F2BF66232A Q34309488-8E2B2A0A-10DA-47DB-9E38-2A3E464F2C43 Q35588352-328E2FAD-AB23-47B0-9E6C-CFF37440F76E Q35818491-E369187A-72E6-4AE5-B436-50335446239D Q36020900-749EE479-A553-4330-930E-4965F1E253D3 Q36102008-314CE124-08A6-4328-A27B-67FA4B5201FA Q36144711-845E83C7-F5BF-40C9-9FA1-BA2F40E71A8F Q36160278-DC948ED3-2BA5-4BCD-BE0C-8D52F0342A38 Q36490203-AD9CBE9D-7A33-4C67-8A2B-DCD070E5684C Q36743450-6223ECAC-D94B-4132-A3C9-D4D4A1A373BC Q36854062-9A166129-1C49-4C1F-9FE5-A943175AD5CF Q37269217-C38F167D-463B-4DA3-89E5-978084A04E37 Q37362118-C2133F65-C8D1-446C-9265-94D7BCB9195A Q37438751-1310CD74-8D11-4213-8F96-E7954E167928 Q37620662-D6BF6EA0-D502-4C4E-9E78-EB9FF3EF65FF Q37623863-A1AA797E-598F-4965-8943-2A734C9EC74F Q38080153-4045B518-ADE8-4649-8334-391131487271 Q38100299-FBBA41A7-1B57-4353-8F09-CE78180B234E Q38152942-0C3F491D-6C27-4F2E-A342-E165178F148E Q38224266-5763D86E-E026-4028-8AC9-A8BD84870795 Q38596368-843DA914-55A4-4B12-AD9D-83C0FE9C0DE3 Q38612128-3662A4D8-BC33-43A8-967B-FF3E717E64CB Q39034710-591388EC-8097-4C10-B247-E72BAB662BC1 Q39155735-268A4ED3-558E-466B-9BD4-0666DFF2A79E Q39497723-BE507A54-534E-43AE-BEF9-EE258F5A7B7C Q40105033-1EF09DCF-95E5-4DCE-8F0D-E3E8775B7459 Q40465701-0BDF5C59-318F-4586-B13D-E7E880C66986 Q41309782-5ED53727-5554-4965-B203-8D03A99AB6B4 Q41527706-85D6769A-3B93-465C-B83E-19F6E66C2281 Q42107579-8D8FE320-F1E3-4758-8159-A7E5B839228F Q42700663-701AC725-912C-4320-A6DE-479F0A296219 Q42739081-16311E9B-A317-4A6E-AD0E-04047E9EDB54 Q47761787-0C459454-3A67-4194-806C-3123C1AC9B84 Q52604402-39A49774-E9C6-4274-A748-41DE2BB6B895

P2860

Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells

http://www.wikidata.org/entity/Q34978267

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Differential anti-proliferative activities of poly

@nl

Differential anti-proliferativ ...... e-negative breast cancer cells

@ast

Differential anti-proliferativ ...... e-negative breast cancer cells

@en

type

label

Differential anti-proliferative activities of poly

@nl

Differential anti-proliferativ ...... e-negative breast cancer cells

@ast

Differential anti-proliferativ ...... e-negative breast cancer cells

@en

prefLabel

Differential anti-proliferative activities of poly

@nl

Differential anti-proliferativ ...... e-negative breast cancer cells

@ast

Differential anti-proliferativ ...... e-negative breast cancer cells

@en

P1433

Q34978267-CE7B520A-4C29-4677-9D11-BC9272911713

P1476

Q34978267-14C96C9F-AB0A-4BB1-A916-8B26ABFF74C1

P2093

Q34978267-0D48D9D8-4605-4908-BCD7-A0E593D17F6E

Q34978267-4DD8D541-61E6-46B8-81AD-3216FAEB87D1

Q34978267-805BFBC7-F6CB-4F8D-B910-943DB40B44B8

Q34978267-BE3AD244-849C-4A9D-9B15-C17429329D87

Q34978267-C8F71AB9-5928-4E88-92B3-2D00556C2DE6

P2860

Q34978267-04C6E97F-30E4-425F-BC05-CE9E42E67352

Q34978267-1CAF5B65-4EE1-4BEF-BA26-3588692883C0

Q34978267-1EDB508A-DD1B-4448-9CF6-41A827DDD593

Q34978267-252E8F2A-E6C7-43BF-82B6-1A6C536EF8F6

Q34978267-253383F4-CF89-4D44-8171-E45161727182

Q34978267-2793C9E0-69A9-41B2-919D-A8541A0B201E

Q34978267-2A242361-824C-4EE2-8C8A-10E5DF92FD9E

Q34978267-2FC3828F-5834-4AC1-9101-4408B23DBCB3

Q34978267-385A2913-77A9-4613-BEBC-BE05A2CF50F4

Q34978267-47E68810-10E1-4423-8C2F-02233DCC780E

P2888

Q34978267-68E0A213-0C6E-4FE1-B540-AED7F9100786

P304

Q34978267-6A356382-EE31-4325-A3EE-6D811D70794E

P31

Q34978267-4031B434-4220-4319-9821-2993CD3E02FB

P356

Q34978267-40DE96B2-3B3A-48F2-9128-823FA0CAF51F

P407

Q34978267-BFB22694-A845-400B-9BA1-CA801C671D86

P433

Q34978267-9C57D5D5-958D-4C6A-998B-AEAE5E28CCDC

P478

Q34978267-2C6A5357-5287-4335-9C4C-B89F9853122B

P577

Q34978267-32EE013A-553A-4C1D-9FBE-25665F6C2709

P6179

Q34978267-22C0801A-EBCC-4FC6-AF8E-F0D31CAC5693

P698

Q34978267-317B6535-5175-4901-A859-E254F5FBD356

P932

Q34978267-754F314E-C140-4C6E-B5DB-6E04B39CAF53

P356

S10549-012-2106-5

P1433

Breast Cancer Research and Treatment

P1476

Differential anti-proliferativ ...... e-negative breast cancer cells

@en

P2093

Charles L Shapiro

http://www.w3.org/2001/XMLSchema#string

Ching-Shih Chen

http://www.w3.org/2001/XMLSchema#string

Hsiao-Ching Chuang

http://www.w3.org/2001/XMLSchema#string

Naval Kapuriya

http://www.w3.org/2001/XMLSchema#string

Samuel K Kulp

http://www.w3.org/2001/XMLSchema#string

P2860

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

PARP inhibitors stumble in breast cancer

PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

PARP inhibition: PARP1 and beyond

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle.

P2888

s10549-012-2106-5

P304

649-659

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-012-2106-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

134

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1020529108

http://www.w3.org/2001/XMLSchema#string

P698

22678161

http://www.w3.org/2001/XMLSchema#string

P932

4297209

http://www.w3.org/2001/XMLSchema#string